Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Geographic Atrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Geographic Atrophy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-007705-37 Sponsor Protocol Number: C-08-36 Start Date*: 2009-08-13
    Sponsor Name:Alcon Research, Ltd
    Full Title: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic atrophy secondary to AMD
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019183-36 Sponsor Protocol Number: CFD4870g Start Date*: 2011-06-16
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE Ib/II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM INJECTION−CONTROLLED STUDY OF SAFETY, TOLERABILITY, AND EVIDENCE OF ACTIVITY OF FCFD4514S INTRAVITREAL INJECTIONS ADMINISTERED MONTHLY OR...
    Medical condition: Geographic Atrophy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000106-35 Sponsor Protocol Number: GX29185 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) SE (Completed) NL (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000578-41 Sponsor Protocol Number: GX28198 Start Date*: 2012-12-05
    Sponsor Name:GENENTECH, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB (FCFD4514S) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO HAVE COMPLETED GENENTECH-SPONSORED LA...
    Medical condition: Geographic Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161390 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000107-27 Sponsor Protocol Number: GX29176 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Completed) BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000423-13 Sponsor Protocol Number: GX30191 Start Date*: 2016-10-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HA...
    Medical condition: Geographic Atrophy secondary to age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161390 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) AT (Completed) SE (Completed) DE (Prematurely Ended) PL (Prematurely Ended) ES (Completed) SK (Prematurely Ended) BE (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002860-59 Sponsor Protocol Number: ISEE2009 Start Date*: 2022-12-08
    Sponsor Name:IVERIC bio, Inc.
    Full Title: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Co...
    Medical condition: geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003991-56 Sponsor Protocol Number: OPH2003 Start Date*: 2016-04-15
    Sponsor Name:IVERIC bio
    Full Title: A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimuraâ„¢ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary t...
    Medical condition: Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075567 Dry age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) EE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005174-94 Sponsor Protocol Number: ISIS696844-CS5 Start Date*: 2021-08-18
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geogr...
    Medical condition: Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002931-32 Sponsor Protocol Number: APL2-GA-305 Start Date*: 2021-09-17
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001436-22 Sponsor Protocol Number: APL2-303 Start Date*: 2018-12-07
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A...
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000676-38 Sponsor Protocol Number: ISEE2008 Start Date*: 2020-06-17
    Sponsor Name:IVERIC bio, Inc.
    Full Title: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients wit...
    Medical condition: geographic atrophy secondary to dry age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075567 Dry age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) HU (Completed) EE (Completed) LV (Completed) PL (Completed) CZ (Completed) ES (Completed) IT (Completed) SK (Prematurely Ended) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001198-22 Sponsor Protocol Number: ALXN2040-GA-201 Start Date*: 2021-12-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004952-12 Sponsor Protocol Number: 4429-202 Start Date*: 2013-04-05
    Sponsor Name:Acucela Inc.
    Full Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy ...
    Medical condition: Geographic atrophy associated with dry age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001435-52 Sponsor Protocol Number: APL2-304 Start Date*: 2018-12-10
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A...
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003987-22 Sponsor Protocol Number: GT-ORACLE Start Date*: 2022-11-08
    Sponsor Name:Gyroscope Therapeutics Ltd.
    Full Title: ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored anteceden...
    Medical condition: Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT-005-1 (FOCUS), GT-005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IE (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002608-97 Sponsor Protocol Number: Start Date*: 2015-09-09
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Five year observational follow-up of the IVAN trial cohort: a study of function and morphology
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001487-37 Sponsor Protocol Number: 190342-032D Start Date*: 2008-11-05
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br...
    Medical condition: Geographic Atrophy from Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000823-42 Sponsor Protocol Number: B1181003 Start Date*: 2013-02-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO CONTROLLED, MULTI-DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RN6G (PF 04382923) IN SUBJECTS ...
    Medical condition: Advanced, Dry, Age-Related Macular Degeneration including Geographic Atrophy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:33:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA